Prescription of off-label medications in patients on dialysis: time to challenge contraindications?

Maxime Touzot¹, Sonia Amato², Christophe Ridel³, Pablo Ureña-Torres⁴

¹Owkin, Biomedical department, Paris, France.

²Aura Paris Plaisance, Paris, France.

³FME Global Medical Office, Fresnes, France.

⁴AURA Nord Saint Ouen, Saint Ouen, Francia and Department of Renal Physiology, Necker Hospital, University of Paris Descartes, Paris, France.

PubMed PMC DOI PDF

Abstract

Prescribing off-label medications for patients undergoing dialysis presents significant clinical challenges that require careful judgement to optimize the risk-benefit ratio. The altered pharmacokinetic profile in this population, characterized by impaired renal elimination, modified non-renal clearance pathways, and complex polypharmacy, has traditionally led to numerous contraindications, not so…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.